Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Phytomenadione→

Phytomenadione Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
84-80-0
Molecular formula
C31H46O2
Molecular weight
450.7 g/mol
Drug class
Vitamin K1fat-soluble vitamin and antihaemorrhagic replacement agent
Mechanism of action
Acts as an essential cofactor for hepatic gamma-glutamyl carboxylation of clotting-factor precursors, enabling formation of functional coagulation factors II, VII, IX and X and regulatory proteins C and S.
Indications / reported uses
  • Treatment of vitamin K deficiency and hypoprothrombinaemia caused by vitamin K deficiency or interference with vitamin K activity.
  • Reversal of coumarin- or indanedione-associated hypoprothrombinaemia, with dose and route selected according to the clinical situation.
  • Prevention and treatment of vitamin K deficiency bleeding in newborns with appropriate formulations.

Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=54c1c1df-0e65-4da8-9023-6cbaa0f5bd0d · https://medicalguidelines.msf.org/sites/default/files/pdf/guideline-339-en.pdf · FDA product information

View request basketPrefer email? [email protected]
Phase IPhase II where requiredEU / UK / other marketsRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

Vitamin K1; fat-soluble vitamin and antihaemorrhagic replacement agent

Mechanism of action

Acts as an essential cofactor for hepatic gamma-glutamyl carboxylation of clotting-factor precursors, enabling formation of functional coagulation factors II, VII, IX and X and regulatory proteins C and S.

General use cases

  • Treatment of vitamin K deficiency and hypoprothrombinaemia caused by vitamin K deficiency or interference with vitamin K activity.
  • Reversal of coumarin- or indanedione-associated hypoprothrombinaemia, with dose and route selected according to the clinical situation.
  • Prevention and treatment of vitamin K deficiency bleeding in newborns with appropriate formulations.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

ERA assessment scope

Project-specific environmental risk assessment support

The pathway is agreed for the medicinal product, intended market, use assumptions and available environmental evidence.

  • Phase I exposure screening and trigger evaluation.
  • Environmental fate and ecotoxicity review, with Phase II work where required.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant.
  • Data-gap review and a report documenting evidence, assumptions, uncertainties and conclusions within the agreed scope.
Assessment scope

Environmental Risk Assessment (ERA)

ReguSight provides project-specific support for the Phytomenadione Environmental Risk Assessment (ERA) (the Phytomenadione ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.